SynthesisCancer reports (Hoboken, N.J.)2026
New Primary and Secondary Prevention Measures for Cutaneous Melanoma: A Systematic Review.
Synthesis in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCutaneous melanoma is the deadliest type of skin cancer, with increasing incidence and mortality rates. Therefore, primary and secondary prevention are of utmost importance. CLAIMS: The objective is to evaluate new recent evidence on primary and secondary prevention strategies for cutaneous melanoma.
methodsSearch of PubMed, Web of Science and EBSCOhost databases retrieved studies from February 2020 to January 2026, on prevention at both primary and secondary levels and that followed the PICO criteria selection process in the PRISMA method for a systematic review. Different assessment tools were used to evaluate methodological quality.
resultsA total of 404 citations were analysed, of which 24 studies met the inclusion criteria: 3 addressed primary prevention and 21 secondary prevention. Primary prevention found a possible chemopreventive agent and the possibility of a genetic control of the mechanisms of nevi fluctuation in life associated with height. The secondary prevention studies evaluated population-based screening strategies and emerging diagnostic tools, artificial intelligence (AI)-assisted tools included, and found a new wearable microneedle biosensor for in situ tyrosinase activity detection as a new approach for early cutaneous melanoma detection. It is clearly a limited primary prevention publication that shows poor new evidence for conclusions.
conclusionsTwo new primary prevention approaches were identified, but both require further research before clinical implementation: aspirin as a potential chemoprotective agent and a possible genetic association between height and age-related nevus regression. Both require further study. Emerging diagnostic technologies, including AI-assisted tools and wearable biosensors for in situ tyrosinase detection, demonstrated high sensitivity but variable specificity, requiring further validation before routine clinical use. Population-based screening, patient education and risk-stratified surveillance improved early melanoma detection, particularly among high-risk populations. Most studies achieved moderate to high methodological quality, but diagnostic accuracy studies revealed some issues showing that require relevant improvements in diagnostic accuracy and standardization. The use of biomarkers is a promising new tool for early diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.